A Phase 1, Multicenter, Open-Label, Dose Escalation Study Evaluationg the Safety and Tolerability of EZN-2968, a Locked Nucleic Acid Antisense Oligonucleotide Against Hypoxia Inducible Factor-1 alpha (anti-HIF-1 alpha LNA AS-ODN), Administered as a Daily 2-Hour Intravenous Infusion x 5 Days Every 4 Weeks in Adult Patients with Advanced Solid Tumors or Lymphoma

Trial Profile

A Phase 1, Multicenter, Open-Label, Dose Escalation Study Evaluationg the Safety and Tolerability of EZN-2968, a Locked Nucleic Acid Antisense Oligonucleotide Against Hypoxia Inducible Factor-1 alpha (anti-HIF-1 alpha LNA AS-ODN), Administered as a Daily 2-Hour Intravenous Infusion x 5 Days Every 4 Weeks in Adult Patients with Advanced Solid Tumors or Lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2008

At a glance

  • Drugs RG 6061 (Primary)
  • Indications Lymphoma; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Nov 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top